Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 11/20 | 0.50 |
| ▸ | SNCA | P37840 | 6/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4319960 | 1.00 | ELANE (0.50) | ELANESNCAF2PLAUNPC1 | |
| SCHEMBL4315179 | 0.74 | KDR (0.59) | SNCA | |
| SCHEMBL4315173 | 0.74 | KDR (0.59) | SNCA | |
| SCHEMBL28327450 | 0.72 | SNCA (0.81) | SNCANPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29537463 | 0.72 | SNCA (0.81) | SNCANPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11048445 | 0.71 | SNCA (0.65) | SNCANPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7666647 | 0.70 | SNCA (0.59) | SNCANPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL18046509 | 0.70 | SNCA (0.62) | SNCANPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5429856 | 0.70 | SNCA (0.62) | SNCANPC1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6282592 | 0.69 | ELANE (0.53) | ELANEF2PLAURORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101111483-B | IGF-1R inhibitors | KYOWA HAKKO KIRIN CO.,LTD. (JP) | 2011-12-14 | — | — | CN | disclosed |
| US-7605272-B2 | IGF-1R inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20090054508-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| CN-101111483-A | IGF-1R inhibitors | KYOWA HAKKO KOGYO KK (JP) | 2008-01-23 | — | — | CN | disclosed |
| EP-1847532-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054508-A1 | IGF-1R INHIBITOR | IGF1R, IGFBP5, IGFBP1 | ELANE 4344/4885SNCA 4866/4885F2 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.